BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12693029)

  • 1. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.
    Stiborová M; Stiborová-Rupertová M; Borek-Dohalská L; Wiessler M; Frei E
    Chem Res Toxicol; 2003 Jan; 16(1):38-47. PubMed ID: 12693029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
    Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
    Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
    Stiborová M; Bieler CA; Wiessler M; Frei E
    Biochem Pharmacol; 2001 Dec; 62(12):1675-84. PubMed ID: 11755121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
    Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
    Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
    Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
    Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
    Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
    Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor drug ellipticine inhibits the activities of rat hepatic cytochromes P450.
    Aimová D; Stiborová M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):437-40. PubMed ID: 16601806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
    Stiborová M; Breuer A; Aimová D; Stiborová-Rupertová M; Wiessler M; Frei E
    Int J Cancer; 2003 Dec; 107(6):885-90. PubMed ID: 14601046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney.
    Stiborova M; Moserova M; Mrazova B; Kotrbova V; Frei E
    Neuro Endocrinol Lett; 2010; 31 Suppl 2():26-35. PubMed ID: 21187821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
    Stiborová M; Rupertová M; Aimová D; Ryslavá H; Frei E
    Toxicology; 2007 Jul; 236(1-2):50-60. PubMed ID: 17482743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
    Martinkova E; Dontenwill M; Frei E; Stiborova M
    Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
    Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
    Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
    Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
    Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of hepatic cytochrome b
    Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.
    Frei E; Bieler CA; Arlt VM; Wiessler M; Stiborová M
    Biochem Pharmacol; 2002 Jul; 64(2):289-95. PubMed ID: 12123750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
    Sulc M; Mrizova I; Cerna T; Frei E; Eckschlager T; Adam V; Kopeckova K; Stiborova M
    Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):95-102. PubMed ID: 28263536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzymes involved in the metabolism of the carcinogen 2-nitroanisole: evidence for its oxidative detoxication by human cytochromes P450.
    Miksanová M; Sulc M; Rýdlová H; Schmeiser HH; Frei E; Stiborová M
    Chem Res Toxicol; 2004 May; 17(5):663-71. PubMed ID: 15144223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
    Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidation of an antitumor drug ellipticine by peroxidases.
    Poljaková J; Forsterová K; Sulc M; Frei E; Stiborová M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):449-53. PubMed ID: 16601808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.